Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: Longitudinal follow-up from a prospective trial

BJU International

Volumn 111, Issue 6, 2013, Pages 988-996

  Ploussard, Guillaume ^a   Nicolaiew, Nathalie ^a   Marchand, Charles ^a   Terry, Stéphane ^a   Allory, Yves ^a   Vacherot, Francis ^a   Abbou, Claude Clément ^a   Salomon, Laurent ^a   De La Taille, Alexandre ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

criteria; detection rate; low risk; prostate cancer; repeat biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; REPEAT PROCEDURE; RISK ASSESSMENT; RISK FACTOR; TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84876903863     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11607.x     Document Type: Article

References (23)

1. Scattoni V, Raber M, Capitanio U, et al. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol 2011; 60: 834-841
2. Campos-Fernandes JL, Bastien L, Nicolaiew N, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009; 55: 600-606
3. Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E,. Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol 2010; 28: 1714-1720
4. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW,. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 2003; 170: 1184-1188
5. Chun FK, Briganti A, Graefen M, et al. Development and external validation of an extended repeat biopsy nomogram. J Urol 2007; 177: 510-515
6. Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000; 163: 1144-1148
7. Garzotto M, Park Y, Mongoue-Tchokote S, et al. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer 2005; 104: 1911-1917
8. Walz J, Graefen M, Chun FK, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: 498-505
9. de la Taille A, Antiphon P, Salomon L, et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003; 61: 1181-1186
10. Bastian PJ, Mangold LA, Epstein JI, Partin AW,. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101: 2001-2005
11. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
12. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ,. Infectious complications and hospital admissions after prostate biopsy in a european randomized trial. Eur Urol 2012; 61: 1110-1114
13. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 2012; 344: d7894
14. Moreira DM, Gerber L, Thomas JA, Bañez LL, McKeever MG, Freedland SJ,. Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. Int J Urol 2012; 19: 741-747
15. Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ,. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int 2012; 109: 508-513
16. Auprich M, Augustin H, Budäus L, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 2012; 109: 1627-1635
17. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM,. An empirical évaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011; 103: 462-469
18. Schröder FH, van den Bergh RC, Wolters T, et al. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol 2010; 57: 256-266
19. Kopp RP, Stroup SP, Schroeck FR, et al. Are repeat prostate biopsies safe? A cohort analysis from the SEARCH Database. J Urol 2012; 187: 2056-2060
20. O'dowd GJ, Miller MC, Orozco R, Veltri RW,. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000; 55: 553-559
21. Carver BS, Bozeman CB, Simoneaux WJ, Venable DD, Kattan MW, Eastham JA,. Race is not a predictor of prostate cancer detection on repeat prostate biopsy. J Urol 2004; 172: 1853-1855
22. Ploussard G, Plennevaux G, Allory Y, et al. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World J Urol 2009; 27: 587-592
23. Ploussard G, Bastien L, Descazeaud A, et al. Extended biopsy protocol decreases prostate cancer incidence and risk of aggressive disease on repeated biopsies compared with initial standard procedure. Urol Int 2010; 84: 147-152